STEVENSON, Md., Feb. 08, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Arizona on behalf of purchasers of Insys Therapeutics, Inc. (Nasdaq:INSY) (“Insys” or the “Company”) common stock during the period between March 3, 2015 and January 25, 2016, inclusive (the “Class Period”). Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until April 4, 2016 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Insys common stock purchased on or after March 3, 2015 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company common stock during the Class Period. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company was engaged in the illegal and improper off-labeling marketing of Subsys and that certain Insys employees’ were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys.
According to the complaint, following the January 25, 2016 revelation that Insys executives continued to pressure Company employees to develop new schemes to promote the illegal and improper off-label marketing and sale of Subsys, the value of Insys shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Google Secures Pentagon AI Deal for Classified Projects
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 



